IRCT2013112913932N2已完成未知
Comparision of maintenance therapy and continuous intravenous therapy with magnesium sulfate in preterm labor pain management at 24-36 weeks gestation: a randomized controlled trial
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- Female
入选标准
- •gestational age of 24 - 36 weeks;the presence of atleast 4 uterus contraction during 20 min; dilatation below 4 cm; effacement less than 80%
- •Exclusion criteria:coexistense of medical disease such as diabetes mellitus; asthma; cardiovascular disease; preeclampsia; uterine bleeding; rupture of membrane; placenta decolman; intruterine infections; UTI; fetus anomalies; previous preterm labor pain; lack of decreasing uterus contractions during 2 first hr after administration of magnesium sulfate; The patient need to administration of magnesium sulfate after 24 h.
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
Comparison of the sequential maintenance therapy with Mycophenolat and Prednisolon to standard therapy after completed induction therapy – a multicenter, randomised, phase III intervention study for progressive IgA-NephritisEUCTR2007-000443-99-DEniversitätsklinikum Ulm
进行中（未招募）
1 期
A Phase IIIb, randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression and observation in patients with relapsed or refractory, indolent non-Hodgkin's lymphoma who completed and responded to rituximab-based immunochemotherapy induction and initial 2-year rituximab maintenance therapy administered subcutaneously.Patients with relapsed or refractory CD20+ follicular non-Hodgkin’slymphoma (NHL) Grade 1, 2 or 3a, or other CD20+ indolent NHL(Waldenström’s macroglobulinemia or lymphoplasmacytic lymphoma,marginal zone lymphoma), according to the WHO classificationsystem.MedDRA version: 20.0Level: LLTClassification code 10067070Term: Follicular B-cell non-Hodgkin's lymphomaSystem Organ Class: 100000013103EUCTR2010-023407-95-DEF. Hoffmann-La Roche Ltd700
进行中（未招募）
1 期
A randomized study comparing maintenance therapy withsubcutaneous rituximab continued until progression with observation only in patients with relapsed or refractory, indolent non-Hodgkin’s lymphoma who completed and responded to rituximab-based immunochemotherapy induction and initial 2-year rituximab maintenance therapy administered subcutaneously.Patients with relapsed or refractory CD20+ follicular non-Hodgkin's lymphoma (NHL) Grade 1, 2 or 3a, or other CD20+ indolent NHL (Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma, marginal zone lymphoma), according to the WHO classification system, or other not further classified low malignant lymphoma by immunohistochemistry.MedDRA version: 14.1Level: PTClassification code 10061170Term: Follicle centre lymphoma, follicular grade I, II, IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-023407-95-ITROCHE692
进行中（未招募）
1 期
A Phase IIIb, randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression and observation in patients with relapsed or refractory, indolent non-Hodgkin’s lymphoma who completed and responded to rituximab-based immunochemotherapy induction and initial 2-year rituximab maintenance therapy administered subcutaneously.EUCTR2010-023407-95-ATF. Hoffmann-La Roche Ltd700
进行中（未招募）
1 期
A Phase IIIb, randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression and observation in patients with relapsed or refractory, indolent non-Hodgkin’s lymphoma who completed and responded to rituximab-based immunochemotherapy induction and initial 2-year rituximab maintenance therapy administered subcutaneously.Patients with relapsed or refractory CD20+ follicular non-Hodgkin’s lymphoma (NHL) Grade 1, 2 or 3a, or other CD20+ indolent NHL (Waldenström’s macroglobulinemia or lymphoplasmacytic lymphoma, marginal zone lymphoma), according to the WHO classification system.MedDRA version: 20.0 Level: LLT Classification code 10067070 Term: Follicular B-cell non-Hodgkin's lymphoma System Organ Class: 100000013103EUCTR2010-023407-95-GBF. Hoffmann-La Roche Ltd692